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Abstract
Background: We aimed to ascertain if Gastrokine 1 mRNA in the sera of patients with gastric cancer might be an
informative biomarker for the disease.
Results: Analysis of GKN1 mRNA in serum samples from healthy individuals (n = 23) and from patients with
diagnosis of gastric cancer (n = 16), performed by using absolute quantification based on standard curve method,
did not show any significative statistical difference between the two unpaired group of individuals.
Conclusions: Our preliminary results did not confirm GKN1 as a potential biomarker for gastric cancer.
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Background
Gastric cancer (GC) is still one of the prevalent leading
causes of cancer-related deaths worldwide and high mor-
tality rate is mainly due to late-stage diagnosis [2]. Sur-
vival rate at 5 years of about 20 % in most areas of the
world [6, 11, 32], except in Japan where mass screening
programs, staging systems, and treatment may contrib-
ute to superior 5-year survival rates of approximately
60 % [30, 35, 37]. In all Europe, the incidence is about
104,620 and 69,394 among males and females, respect-
ively [16], representing about 23 % of all cancers.
The most common type of stomach cancer is adeno-
carcinoma, which is divided into intestinal (well-differ-
entiated) and diffuse (undifferentiated) each having
different epidemiological and pathophysiological features
[20]. The intestinal-type generally evolves through a
relatively well-defined sequence of histological lesions,
namely non-atrophic gastritis, chronic atrophic gastritis,
intestinal metaplasia, and dysplasia [4, 5]. On the con-
trary, the diffuse-type has instead a poorer prognosis
and develops through unknown genetic and morpho-
logical events from normal gastric epithelium. The
pathogenesis of GC remains poorly understood however
several environmental factors, such as Helicobacter pyl-
ori (H. pylori) infection can be the cause leading to this
disease. This risk is probably the result of a combination
of genetic and environmental factors in which the infec-
tion by H. pylori is of particular relevance.
In a previous work, we analyzed the protein profile of
malignant and normal gastric tissues and identified a
novel stomach specific protein gastrokine 1 (GKN1)
whose expression was reduced in H. pylori infected gastric
mucosa and down-regulated or completely absent in GC
tissues and precancerous lesions. [13, 28]. GKN1 belongs
to a family of genes encoding stomach-specific proteins
formed by 3 known members: GKN1 [23], GKN2 [9], and
GKN3 [26]. These proteins, besides a highly conserved
structure, show convergent functions in terms of modula-
tion of gastric mucosal homeostasis and inflammation, ac-
tivity in epithelial wound healing and/or repair, and anti-
proliferative activity. Moreover, they are highly expressed
in the normal stomach and loss of GKNs expression in
gastric cancers suggests putative tumor suppressor roles
[24]. For instance, GKN2 knockout mice showed defective
gastric epithelial differentiation whereas, loss of GKN2 in
gp130F/F caused tumorigenesis of the proximal stomach.
Furthermore, in H. pylori–infected GKN2 knockout mice,
gastric immunopathology was accelerated and associated
with augmented T helper cell type 1 (Th1) [25]. However,
GKNs modes of action remain unsolved. Some findings
indicated the involvement of GKN1 in the replenishment
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of the surface lumen epithelial cell layer, and in maintain-
ing mucosal integrity [36]. After injury of the gastric mu-
cosa, restoration may occur very rapidly in the presence of
GKN1. In contrast, if the protein is down-regulated the re-
pair process may be hampered [19]. Application of GKN1
to gastrointestinal cells promoted epithelial restoration
and exerted its protective effect by increasing accumula-
tion of specific tight and adherens junction proteins and
also protecting their loss after injury [33].
Under this consideration, GKN1 might represent an
important biomarker in carcinogenic process since it
was seen that individuals with a lower expression of the
protein have an increased risk to develop gastric dis-
eases. We hypothesized that GKN1 mRNAs identified
in serum of GC patients could become a completely
non-invasive biomarker potentially distinguishing GC
patients from healthy individuals.
Results and discussion
GKN1, also called Antrum Mucosal Protein of 18 kDa
(AMP-18) [40], is considered one of the most putative
gastric cancer biomarkers [43]. Its low expression can be
concluded in onset of malignancy. Moreover, while its
presence in H. pylori negative patient is normal, it is de-
creased in H. pylori-positive patients [28]. Because hu-
man serum is a rich source of biochemical products that
can act as indicators of the physiological or clinical sta-
tus of a patient, we exploited the potentiality of GKN1
as gastric cancer biomarker trying to highlight its pres-
ence in human serum. We first used Western blotting
technique to analyze human sera of healthy individuals.
Because of the unusually high abundance of human
serum albumin (HSA) in serum that can interfere with
the resolution and sensitivity of several proteome tech-
niques, samples were partially purified by Centricon 30
to remove high molecular weight proteins and then ana-
lyzed by Western blotting comparing the intensity of the
signals with that of human gastric mucosal extract. De-
tection with monoclonal mouse anti-GKN1 antibody did
not show any positive band signals compared to that
shown by human gastric mucosal extract (from data not
shown). This result was also confirmed by analyzing the
same serum samples with ELISA kit for GKN1. Al-
though its lower limit of detection (0.056 ng/mL), no ab-
sorbance was observed in all sera analyzed (from data
not shown). Because the given detection limit of both
GKN1 antibody and ELISA kit is about 0.15 ng/mL
(using as control recombinant GST tagged GKN1), the
lack of detection of GKN1 in human sera, unless it is to-
tally absent, might probably depends by a far lower con-
centration of the protein. Therefore, more sensitive
methods for the detection of the protein in the serum
should be used in order to ascertain this possibility.
The above results prompted to search for GKN1 at
transcription level. It is well known that mRNA in body
fluid such as blood, has been proved as a novel resource
to replace conventional tools for disease identification
[15, 21, 27], and successfully used as cancer-related bio-
marker [1, 31, 39]. In fact, mRNA markers have been
the targets for identifying patients with colorectal,
breast, lung, and thyroid cancers, and malignant melan-
oma [3, 12, 17, 18, 40]. All these published studies were
performed for testing a single mRNA marker, however
no much is known about the nature of circulating extra-
cellular RNA (exRNA), including mRNA, and the pos-
sible mechanisms by which these RNAs are protected
from plasma RNase activity [10]. One possible hypoth-
esis is that exRNA present in plasma/serum are stabi-
lized through binding to protein/lipoprotein complexes
or that that are sequestered within lipid vesicles [14]. In
this scheme, we tried to assess if GKN1 circulating
mRNA in serum might represent a biomarker for gastric
cancer detection. Therefore, we first tried to detect the
presence of GKN1 mRNA in sera of healthy volunteers.
Four sets of PCR primers (F1-R1, F2-R2, F3-R3 and F4-
R4), covering GKN1 coding sequence at exon and intron
bounda [32] of GKN1 gene, were defined by using Pri-
merBlast Server (Fig. 1) and used to perform semi-
quantitative PCR on fresh human sera. As reported in
Fig. 2 (lanes a), all primer couples were able to amplify
the corresponding GKN1 cDNA region giving PCR
products of the expected length. This finding suggested
the presence of a full GKN1 mRNA in the samples ana-
lyzed and the absence of possible PCR products deriving
from genomic DNA. Because RNA is widely thought to
be labile in the circulation, as reported by [38], we then
analyzed the same blood samples that had been left at
4 °C for 24 h. As shown in Fig. 2 (lanes b), no difference
was observed in the band intensities after repeating the
PCR in the same conditions, thus confirming the general
stability of mRNAs [38]. To check if the four PCR prod-
ucts were corresponding to GKN1 cDNA, PCR sequen-
cing analyses were performed. The results confirmed
that the nucleotide sequences of the four PCR products
were encoding GKN1 (not shown).
Therefore, we decided to use the quantitative real-time
PCR (qRT-PCR) strategy to detect GKN1 mRNA in the
serum obtained from a population of wealthy subject
and in that from patients with diagnosis of gastric can-
cer. We took advantage from a collection of sera with-
drawn from patients with a diagnosis of gastric cancer
that underwent surgical treatment. The clinicopathologic
characteristics of the gastric cancer patients enrolled in
this study are outlined in Table 1. The intestinal type
was well differentiated in one, moderately differentiated
in three and poorly differentiated in the remaining cases,
while as far as concerns stage, these were all advanced.
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Fig. 1 Design of PCR primers for the detection of GKN1 mRNA in human sera. Structure of GKN1 gene and nucleotide sequence of GKN1 mRNA.
The coding region is represented in capital letters, 5′ and 3′ UTR are in lower case, start and stop codons are underlined, intron regions are boxed. PCR
primers pairs F1-R1, F2-R2, F3-R3 and F4-R4 are highlighted in yellow, green, azure and gray, respectively
Fig. 2 Semiquantitative PCR of GKN1 mRNA expression in human sera. Representative semiquantitative PCR performed on a serum of a healthy
subject performed before (lanes a) and after (lanes b) storage of the sample at 4 °C for 24 h. PCR reactions (PCR1, PCR2, PCR3 and PCR4) were
carried out using the primers pairs F1-R1, F2-R2, F3-R3 and F4-R4 as reported in Fig. 1
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Diffuse type GC was poorly differentiated and advanced
in all cases. The non-tumoral areas of intestinal type GC
showed a variable degree of atrophy with diffuse IM, in-
stead, the non-tumoral areas of diffuse type GC showed
a variable degree of non-dysplastic inflammation.
Characterization of non-tumoral gastric mucosa (N)
from tumoral (T) one was based on the macroscopic as-
pect of the normal tissue compared to the tumoral one,
as evaluated from the hospital pathologist. Moreover,
paired specimens of non-tumoral (N) and tumoral (T)
gastric mucosa where analyzed by Western blotting for
GKN1 expression levels. As shown in Fig. 3, compared
to non-tumoral tissues (N), in the corresponding tu-
moral tissues (T) it was observed almost a complete
down-regulation of GKN1 at protein level [8]. To assess
whether the GKN1 down-regulation occurred also at
mRNA level, qRT-PCR analyses were performed on total
RNA extracted from three paired non-tumoral and tu-
moral gastric tissues (Fig. 3c). GKN1 mRNA is one of
the most abundant transcripts known in the normal
stomach (about 1 % of total gastric mRNA), often un-
detectable in gastric tumor tissues by Northern blotting
[29]. However, qRT-PCR is a more sensitive method able
to unveil the presence of low levels of a given mRNA in
cells/tissues [7]. As shown in Fig. 3c, compared to non-
tumoral tissues, qRT-PCR showed a decrease of GKN1
mRNA level in tumoral tissues [42]. Therefore, based on
these findings, our hypothesis was that compared to
healthy subjects, in sera of patients with GC, lower sig-
nificative levels of GKN1 mRNA could have been evalu-
ated by quantitative analysis.
qRT-PCR was performed by absolute quantification by
a standard curve method constructed using as reference
DNA a plasmid containing flGKN1 cDNA [34] and as
primers the F2-R2 pair ( Fig. 4). We used serial 10-fold
dilutions of plasmids to construct a standard curve by
plotting the logarithm of the plasmid copy number
against the measured cycle values. The standard curve
had a wide range of DNA copies/μl (from 3.78 × 101 up
3.78 × 108) with a linear correlation (R2) of 0.99351, and
a slope of −3.909 (Fig. 4a). The level of circulating
GKN1 mRNA of all 23 healthy samples showed a me-
dian cycle number value of 29.6673 (range 27.702–
31.380). GC patients gave a median Ct value of 30.1269
(range 28.713–31.279). The statistical evaluation of the
results using Student t-Test of unpaired data with unequal
variance indicated a non-significant difference between
the two groups (p = 0.1138). From the standard curve, the
mean circulating copies of GKN1 mRNA were 1.81x105
and 2.38 × 105 copies/ml in patients and healthy individ-
uals, respectively (Fig. 4b). Despite the strong down-
regulation of GKN1 protein levels in gastric cancer, the
quite comparable levels of GKN1 mRNA strongly indi-
cated that this down-regulation is not observed at tran-
scription levels thus suggesting translation regulation
mechanism for GKN1 expression. The result obtained
suggested to direct the search towards other non-invasive
gastric cancer biomarker such as long noncoding RNAs
(lncRNAs), a recently discovered class of noncoding RNAs
(ncRNA) that are emerging as a promising new class of
biomarkers for tumour diagnosis [41].
Conclusion
In conclusion, although we have shown for the first time
the presence of GKN1 mRNA in human serum of
Table 1 Characteristics of Healthy Subjects and Gastric Cancer
Patients
Variable Healthya Gastric Cancer
Subjects (n = 23) Subjects (n = 16)
Age (years) 59 ± 25 64 ± 13
Sex ratio (M:F) 8:23 1:6a 14/9 9/7
Tumor type – Intestinal 9, Diffuse 7
Grade of differentiation – Well 1, Moderate 3, Poor 12
Stage – Early 0 (0 %);
Advanced 16 (100 %)
aAll healthy individuals included did not have dyspeptic symptoms
Fig. 3 Expression levels of GKN1 in human gastric tissues. a Representative Western blot of equal amounts of cell extracts (20 μg) analyzed in
paired non-tumoral (N1, N2, N3) and tumoral (T1, T2, T3) human gastric samples using mouse anti-GKN1 (a) and rabbit anti–GAPDH (b) antibodies
(Ab). c qRT-PCR analysis. Total RNA was prepared from gastric tissues and analyzed by qRT-PCR for GKN1 mRNA level. Samples: N and T, non-
tumoral and tumoral gastric tissues, respectively. Data from three experiments are reported as mean values ± SD. * P < 0.05
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healthy subjects as well as in that of patients with diag-
nosis of gastric cancer, when we analyzed by qRT-PCR
these sera, we did not observe significant statistical dif-
ferences among the two population. Therefore, we could
not confirm our hypothesis that GKN1 mRNA could
serve as non-invasive marker for GC.
Methods
Population
The study population comprised 16 patients with GC
recruited at Hospital A. Cardarelli, Naples, Italy. All volun-
teers (23 individuals) were subjected to careful anamnesis
and all those who had dyspeptic symptoms were excluded.
Patients were interviewed regarding smoking habit, alcohol
intake and chronic use of drugs and informed consent
from each patient was obtained. Hospital Pathologist per-
formed the macro dissection of tumor and non-tumor
tissues of GC patients during surgery. Blood samples from
these patients were collected before surgery and soon
stored at −20 °C. Gastric cancer was classified according to
Lauren criteria [20]. The study reported in the manuscript
has been carried out in the frame of a research protocol
entitled “Role of gastrokine 1 in gastric cancer” that has
the approval from the Ethic Committee of the University of
Naples Federico II (Comitato Etico Università Federico II).
The assigned protocol number of the study was 34/15.
Western blotting
Proteins from cell extracts were analyzed by Western
blotting using mouse anti-GKN1 monoclonal antibody,
clone 2E5 (Abnova, Taipei, Taiwan) at a dilution of
1:500. Detection was performed using the enhanced
chemiluminescence detection kit (SuperSignal West
Pico) following manufacturer’s instructions. All films
were analyzed by using the Image J software. Western
blot band intensity was measured with ImageJ 1.46r
software.
Serum samples for Western blotting and PCR analyses
Serum samples from healthy or gastric cancer subjects
were prepared immediately after blood samples with-
drawn and stored at −80 °C. For Western blotting, 1 mL
of serum was diluted 1:1 with H2O and centrifuged at
4,000 rpm in Centricon 30 (Millipore, Darmstadt,
Germany) to separate higher size proteins. Filtered sam-
ple was then lyophilized overnight, re-suspended in
50 μL H2O and analyzed by Western blotting using
mouse anti-GKN1 antibody, or by GKN1 ELISA Kit
(Cloud-Clone Corp, Huston, USA), according to the
manufacturer instruction.
Total RNA from 1 mL of serum sample was prepared
using miRNeasy Serum/Plasma Kit (Qiagen). RNA con-
centration was measured using the NanoDrop 1000
spectrophotometer (Thermo Fisher Scientific). 1 μg of
total RNA was retro-transcribed with the iScript cDNA
Synthesis Kit (Bio-Rad, Milan). 4 μl of cDNA were amp-
lified with 1 unit of Taq DNA Polymerase (Invitrogen) in
the buffer provided by the manufacturer not containing
MgCl2. Reactions were carried out in the PTC-0150
Mini-Cycler (Biorad) according to the following condi-
tion: first cycle of 5 min at 95 °C followed by 30 cycles
(30 s at 95 °C, 40 s at 58 °C, 30 s at 72 °C) and 10 min at
72 °C. GAPDH was used as a control.
For semi-quantitative PCR, the following primers were
designed: F1, cctctgtccactgctttcgt, R1, tggttgcagcaaagc-
cattt; F2, cttcagggtaagggaccag, R2, cttgcctcttgcatctcctca;
F3, ctttctagctcctgccctagc, R3, gttgcagcaaagccatttcc; F4,
caacaatgctggaagt gggc, R4, tcccttaccctgaagttcttt.
For qRT-PCR, GKN1 cDNA was amplified using as
primers F2-R2. qRT-PCR was performed with the SYBR
Fig. 4 qRT-PCR of GKN1 mRNA levels in human sera. a Standard calibration curve constructed using pCDNA3.1 vector containing the cDNA
encoding human GKN1 (pCDNA3.1-flGKN1). b Statistical evaluation of the results of the qRT-PCR performed on human sera from a population of
healthy individuals (N) and from patients with gastric cancer (T)
Villano et al. Journal of Negative Results in BioMedicine  (2016) 15:14 Page 5 of 7
Green PCR MasterMix (Applied Biosystems) under the
following conditions: 10 min at 95 °C, followed by 40 cy-
cles (15 s at 95 °C and 1 min at 60 °C). Each reaction
was performed in duplicate. We used the 2–ΔΔCT
method to calculate the relative expression levels [22].
Results on serum samples were evaluated by absolute
quantitation using a standard curve constructed using
dilution of plasmid pCDNA3.1 containing GKN1 cDNA
(pCDNA3.1-flGKN1) [34].
qRT-PCR and Western blotting from gastric tissues.
Total RNA was extracted from non-tumoral and tu-
moral human tissues using TRIzol reagent solution
(Invitrogen) according to the manufacturer’s protocol.
GKN1 cDNA was amplified by qRT-PCR using F3-R3
primers, as above reported. Protein extracts from gastric
tissues were prepared and analyzed by Western blotting
as described [8].
Statistical analyses
Statistical analyses were performed by two-tailed un-
paired or paired Student’s t-test using KaleidaGraph
4.1.1 software. Data were reported as means ± standard
deviation (SD). The significance was accepted at the
level of p < 0.05.
Abbreviations
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